Leadership

Paul O'Riordan

Chief Executive Officer

Paul is a chartered accountant (Ireland) and holds an MBA (Harvard University), and is a former partner at McKinsey & Co and a co-founder of Synexa.

His role at Synexa encompasses the overall strategic, financial and commercial management of the company; he works closely with our clients to ensure that Synexa’s approach to client service is professional, innovative and focused on bringing demonstrable value to the difficult decisions that clients need to make in new drug development.

Paul’s ambition is to build a global organisation of professional scientists that helps to significantly improve the productivity of new drug R&D, which he believes is the most important strategic issue facing the industry and health care systems throughout the world.
E-mail: poriordan@synexagroup.com

Prof. Patrick Bouic

Chief Scientific Officer

Patrick is a co-founder of Synexa Life Sciences and Extraordinary Professor of Immunology at Stellenbosch University in Cape Town.

In his role as CSO, Patrick’s main focus is on applying the latest developments in biomedical science to the challenges facing our clients and on ensuring the highest quality biomarker analysis across our global lab network. Patrick holds a PhD in immunology from the University of Claude Bernard, Lyon, France and has spent 34 years working on the application of immunopathology to questions of human health.

His professional passion is the development of a new generation of scientists equipped to apply a more integrated understanding of human biology to the diseases and drugs with which we work.
E-mail: pbouic@synexagroup.com

Dr. Justin Devine

Chief Medical Officer

Justin is a medical doctor and pharmacologist (Stellenbosch University), and a co-founder of Synexa.

His primary focus is on understanding our clients’ objectives in new drug development and designing biomarker strategies to bring real insight to the challenges of clinical development. Justin has a very deep understanding of the role that biomarkers and pharmacogenetics can play in understanding the performance of a candidate drug.

He is particular passionate about improving the drug development process by bringing innovative new approaches to early phase research, including new ideas in translational medicine, bioinformatics and artificial intelligence.
E-mail: jdevine@synexagroup.com